Does RUXOLITINIB Cause Second primary malignancy? 611 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 611 reports of Second primary malignancy have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.9% of all adverse event reports for RUXOLITINIB.
611
Reports of Second primary malignancy with RUXOLITINIB
0.9%
of all RUXOLITINIB reports
150
Deaths
159
Hospitalizations
How Dangerous Is Second primary malignancy From RUXOLITINIB?
Of the 611 reports, 150 (24.5%) resulted in death, 159 (26.0%) required hospitalization, and 24 (3.9%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 611 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
METHOTREXATE (414)
Which RUXOLITINIB Alternatives Have Lower Second primary malignancy Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE